MedTrace Logo

Dose Range Finding Study of Bimagrumab in Sarcopenia

NCT02333331 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 217

Last updated 2021-01-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to determine the efficacy of repeat dosing with multiple dose levels of bimagrumab on patient physical function, skeletal muscle mass and strength in older adults with sarcopenia. In addition, this study generated data on the safety, tolerability, and pharmacokinetics of bimagrumab in older adults with sarcopenia.

Conditions

Interventions

DRUG

bimagrumab

Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.

OTHER

placebo

Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-09
Primary Completion
2018-06-26
Completion
2018-06-28
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Czechia
  • Denmark
  • France
  • Germany
  • Japan
  • Russia
  • South Korea
  • Spain
  • Switzerland
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02333331 on ClinicalTrials.gov